We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+11.56%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$8.44B
AUM Growth
+$1.09B
(+15%)
Cap. Flow
+$577M
Cap. Flow
% of AUM
6.84%
Top 10 Holdings %
Top 10 Hldgs %
15.63%
Holding
838
New
218
Increased
181
Reduced
162
Closed
220
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$123M |
| 2 |
HES
Hess
HES
|
+$115M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$108M |
| 4 |
Cencora
COR
|
+$106M |
| 5 |
Microsoft
MSFT
|
+$101M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$108M |
| 2 |
Analog Devices
ADI
|
+$105M |
| 3 |
Keysight
KEYS
|
+$101M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$82.2M |
| 5 |
Booking.com
BKNG
|
+$58.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.55% |
| 2 | Technology | 28% |
| 3 | Industrials | 9.43% |
| 4 | Energy | 7.74% |
| 5 | Consumer Discretionary | 5.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LBPH
501
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $832K | 0.01% |
113,334
-1,235
| -1% | -$9.35K |
|
|
VRNT
502
DELISTED
Verint Systems
VRNT
| $828K | 0.01% |
23,627
+7,852
| +50% | +$283K |
|
503
Apple
AAPL
$4.43T
| $811K | 0.01% |
+4,182
| New | +$729K |
|
504
uniQure
QURE
$3.06B
| $799K | 0.01% |
69,721
-100,989
| -59% | -$1.91M |
|
505
SentinelOne
S
$6.87B
| $795K | 0.01% |
52,638
-16,500
| -24% | -$279K |
|
506
Calix
CALX
$2.35B
| $793K | 0.01% |
15,889
+2,564
| +19% | +$124K |
|
|
KSM
507
DELISTED
DWS Strategic Municipal Income Trust
KSM
| $793K | 0.01% |
93,420
| – | – |
|
508
MSCI
MSCI
$41.8B
| $791K | 0.01% |
+1,685
| New | +$822K |
|
509
DoubleVerify
DV
$1.8B
| $729K | 0.01% |
18,724
+6,194
| +49% | +$200K |
|
510
EXL Service
EXLS
$5.19B
| $725K | 0.01% |
+24,000
| New | +$757K |
|
|
HQL
511
abrdn Life Sciences Investors
HQL
$586M
| $716K | 0.01% |
52,912
| – | – |
|
512
Eledon Pharmaceuticals
ELDN
$265M
| $708K | 0.01% |
516,675
| – | – |
|
513
Upwork
UPWK
$1.18B
| $703K | 0.01% |
75,226
+42,135
| +127% | +$382K |
|
|
IGMS
514
DELISTED
IGM Biosciences
IGMS
| $692K | 0.01% |
75,000
-78,825
| -51% | -$883K |
|
|
SEEL
515
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $686K | 0.01% |
+149
| New | +$517K |
|
516
Rapid7
RPD
$680M
| $671K | 0.01% |
14,816
-215,259
| -94% | -$9.98M |
|
|
RNAM
517
DELISTED
Avidity Biosciences
RNAM
| $645K | 0.01% |
58,121
| – | – |
|
518
Duolingo
DUOL
$6.33B
| $643K | 0.01% |
+4,496
| New | +$644K |
|
|
ERH
519
Allspring Utilities & High Income Fund
ERH
$106M
| $637K | 0.01% |
62,936
+6,131
| +11% | +$63.7K |
|
520
Biogen
BIIB
$29.8B
| $630K | 0.01% |
2,213
-140,865
| -98% | -$41.9M |
|
521
Okta
OKTA
$24.6B
| $627K | 0.01% |
9,040
+2,110
| +30% | +$160K |
|
522
Logitech
LOGI
$15.1B
| $620K | 0.01% |
+10,441
| New | +$632K |
|
523
Vivid Seats
SEAT
$87.5M
| $613K | 0.01% |
3,871
+1,669
| +76% | +$260K |
|
524
BlackLine
BL
$1.92B
| $606K | 0.01% |
+11,259
| New | +$625K |
|
525
Alkami Technology
ALKT
$2.01B
| $597K | 0.01% |
36,410
+18,977
| +109% | +$262K |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Woodline Partners held 838 positions worth $8.44B, up 15% from $7.35B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners deployed $577M of net new capital in Q2 2023, opening 218 new positions and adding to 181 existing holdings. Its largest new stake was Hess: 837,083 shares worth $114M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Keysight, an estimated $101M trimmed.
- Woodline Partners's largest Q2 2023 buy was Hess: 837,083 shares worth $114M.
- Woodline Partners added most to Johnson & Johnson in Q2 2023, an estimated $123M increase.
- Woodline Partners's biggest Q2 2023 reduction was Keysight, cutting an estimated $101M.
- Woodline Partners fully exited Baxter International in Q2 2023, selling an estimated $108M.
- Woodline Partners's ten largest holdings make up 16% of its $8.44B portfolio in Q2 2023.
- Woodline Partners opened 218 new positions and closed 220 in Q2 2023.
- Woodline Partners's portfolio value rose 15% quarter-over-quarter to $8.44B.
Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.